Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: Results from a multicenter, randomized, double-blind, placebo-controlled clinical trial

Cancer

Volumn 92, Issue 4, 2001, Pages 875-885

  Epstein, Joel B ^a,b,k   Silverman Jr , Sol ^c   Paggiarino, Dario A ^d   Crockett, Steve ^e   Schubert, Mark M ^a   Senzer, Neil N ^f   Lockhart, Peter B ^g   Gallagher, Michael J ^h   Peterson, Douglas E ⁱ   Leveque, Francis G ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Università Politecnica delle Marche ACRAF Gruppo Angelini   (United States)

^e DATA Inc   (United States)

^f BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^g CAROLINAS MEDICAL CENTER   (United States)

^h Mercy Hospital   (United States)

ⁱ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^j HARPER UNIVERSITY HOSPITAL   (United States)

^k British Columbia Perinatal Health Program   (Canada)

more..

Author keywords

Benzydamine oral rinse; Head and neck carcinoma; Placebo controlled clinical trial; Radiation therapy

Indexed keywords

BENZYDAMINE; PLACEBO;

ADULT; AGED; AGEUSIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH HYGIENE; MOUTH ULCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; VOMITING; XEROSTOMIA;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZYDAMINE; DOUBLE-BLIND METHOD; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; MOUTHWASHES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; STOMATITIS;

EID: 0035880763     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1     Document Type: Article

References (47)

1. Oral cavity toxicity
2. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx
3. Effects of benzydamine on the oral mucositis during antineoplastic radiotherapy and/or intra-arterial chemotherapy
4. Prevention of oral mucositis in radiation therapy: A controlled study with benzydamine hydrochloride rinse
5. Effects of chlorhexidine rinsing on the oropharyngeal ecology in patients with head and neck cancer who have irradiation mucositis
6. The effects of sucralfate suspension and diphenhydramine syrup plus kaolinpectin on radiotherapy-induced mucositis
7. Oral health care for cancer patients
8. Elapsed radiation therapy treatment time as a predictor of survival in patients with advanced head and neck cancer who receive chemotherapy and radiation therapy
9. Prevention and treatment of chemotherapy-and radiotherapy-induced oral mucositis: A review
10. Defining mechanisms of action of interlukin-11 on the progression of radiation-induced oral mucositis in hamsters
11. The biological basis for interleukin-11 attenuation of oral mucositis
12. A quantitative histometric murine in vivo model of radiation-induced oral mucositis
13. Manifestations and treatment of xerostomia and associated effects secondary to head and neck radiation therapy
14. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor by bacterial lipopolysaccharides
15. Review of pharmacological data on benzydamine
16. A clinical evaluation of benzydamine hydrochloride
17. In vivo metabolism and anti-inflammatory activity of benzydamine hydrochloride in rats treated with carrageenin
18. Research on the topical activity of benzydamine
19. Aspects of the mechanisms of action of benzydamine
20. A controlled study of benzydamine oral rinse in general practice
21. The pharmacology of benzydamine
22. The chemistry of benzydamine
23. The use of benzydamine HCl for the management of cancer therapy-induced mucositis: A preliminary report of a multi-centre study
24. Benzydamine HCl, a new agent for the treatment of radiation mucositis of the oropharynx
25. Benzydamine HCl in the prevention of oropharyngeal mucositis in radiation therapy: Literature review and clinical study
26. The effect of chlorhexidine and benzydamine mouthwashes on mucositis induced by therapeutic irradiation
27. Benzydamine hydrochloride for symptomatic relief of radiation mucositis in the treatment of advanced larynx cancer
28. Benzydamine HCl in the management of chemotherapy-induced mucositis
29. Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine
30. Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells
31. Benzydamine protection in a mouse model of endotoxemia
32. Cancer of the head and neck (general principles of radiation therapy)
33. The management of cancer pain
34. Clinical efficacy of prednisone in the treatment of patients with oral inflammatory ulcerative diseases: A study of fifty-five patients
35. MacDibbs mouth assessment. A new tool to evaluate mucositis in the radiation therapy patient
36. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis
37. Sucralfate mouth washing in the prevention of radiation-induced mucositis: A placebo-controlled double-blind randomized study
38. Management of mucositis in oral irradiation
39. In vitro benzydamine susceptibility testing with time kill assays
40. Bacterial and fungicidal activity in vitro of benzydamine hydrochloride
41. Ultrastructural aspects of Candida albicans after benzydamine exposure in vitro
42. The relationship among fluoride, cariogenic oral flora and salivary flow rate during radiation therapy
43. Risk factors for oropharyngeal candidiasis in patients who receive radiation therapy for malignant conditions of the head and neck
44. Candidal colonization and oral candidiasis in patients undergoing oral and pharyngeal radiation therapy
45. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer
46. Candida albicans levels in patients with Sjogren's syndrome before and after long-term use of pilocarpine hydrochloride: A pilot study